$ACAD

$19.85 +$0.11 (0.56%) Pre-market

$ACAD Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$ACAD Management Team

Dr. Stephen Biggar

Independent Chairman of the Board

Age 54

Compensation $386.1K USD

Sex Male

Ms. Catherine Owen Adams

Chief Executive Officer

Director

Age 54

Compensation $7.594M USD

Sex Female

Mr. Mark Schneyer

Chief Financial Officer

Executive Vice President

Age 51

Compensation $2.518M USD

Sex Male

Ms. Jennifer Rhodes

Executive Vice President

Company Secretary and Chief Legal Officer

Age 54

Compensation $3.267M USD

Sex Female

Mr. Thomas Garner

Executive Vice President

Chief Commercial Officer

Age 49

Compensation $3.671M USD

Sex Male

Dr. Elizabeth Thompson

Executive Vice President and Head of Research and Development

Age 50

Compensation $4.262M USD

Sex Female

Mr. Scott Cenci

Senior Vice President

Chief Information and Data Officer

Age -

Compensation -

Sex Male

Ms. Konstantina Katcheves

Senior Vice President

Chief Business and Strategy Officer

Age -

Compensation -

Sex Female

Ms. Allyson Mcmillan-Youngblood

Senior Vice President - Rare Disease Franchise

Age -

Compensation -

Sex Female

Name / Title	Age	Compensation	Sex
Dr. Stephen Biggar Independent Chairman of the Board	54	$386.1K USD	Male
Ms. Catherine Owen Adams Chief Executive Officer Director	54	$7.594M USD	Female
Mr. Mark Schneyer Chief Financial Officer Executive Vice President	51	$2.518M USD	Male
Ms. Jennifer Rhodes Executive Vice President Company Secretary and Chief Legal Officer	54	$3.267M USD	Female
Mr. Thomas Garner Executive Vice President Chief Commercial Officer	49	$3.671M USD	Male
Dr. Elizabeth Thompson Executive Vice President and Head of Research and Development	50	$4.262M USD	Female
Mr. Scott Cenci Senior Vice President Chief Information and Data Officer	-	-	Male
Ms. Konstantina Katcheves Senior Vice President Chief Business and Strategy Officer	-	-	Female
Ms. Allyson Mcmillan-Youngblood Senior Vice President - Rare Disease Franchise	-	-	Female

Board of Directors

From the proxy statement filed Apr 24, 2026

Directors

serving now

Independent

7 of 8

stated in the proxy

Average tenure

8.0 years

from year joined

CEO also chairs the board

Stephen R. Biggar

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
Stephen R. Biggar Board chair	55	2013 13 years	Independent	None stated	Kiniksa Pharmaceuticals, Ltd., TScan Therapeutics, Inc.	$415,542
Julian C. Baker	59	2015 11 years	Independent	None stated	Incyte Corporation, Madrigal Pharmaceuticals, Inc., Denali Therapeutics, Inc.	$385,049
Laura A. Brege	68	2008 18 years	Independent	Nominating and Corporate Governance Committee · Chair	Edgewise Therapeutics, Inc., Mirum Pharmaceuticals, Inc., Pacira BioSciences, Inc., T-knife Therapeutics, Inc.	$395,212
James M. Daly	64	2016 10 years	Independent	None stated	Argenx SE, Cytokinetics, Incorporated, Madrigal Pharmaceuticals, Inc.	$393,942
Elizabeth A. Garofalo	68	2020 6 years	Independent	None stated	Alector, Inc., Xenon Pharmaceuticals Inc.	$392,671
Adora Ndu	45	2022 4 years	Independent	None stated	DBV Technologies S.A.	$400,294
Jonathan Poole	51	2026 0 years	Independent	None stated	None stated	Not stated
Catherine Owen Adams CEO	55	2024 2 years	Not independent	None stated	Agios Pharmaceuticals, Inc.	Paid as CEO

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed Apr 24, 2026

entities affiliated with Baker Bros. Advisors LP

holders of more than 5% of our capital stock; affiliated with directors Mr. Baker and Dr. Biggar

Amount not stated

Registration rights agreements (dated January 6, 2016 and February 24, 2026) providing certain holders of capital stock with registration rights, including demand and piggyback rights.

Open in proxy

Comments

Company Executives

$ACAD Management Team

Dr. Stephen Biggar

Ms. Catherine Owen Adams

Mr. Mark Schneyer

Ms. Jennifer Rhodes

Mr. Thomas Garner

Dr. Elizabeth Thompson

Mr. Scott Cenci

Ms. Konstantina Katcheves

Ms. Allyson Mcmillan-Youngblood

Board of Directors

Related-party transactions